Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

Astellas and Yaskawa are establishing a joint venture for the development of a cell therapy product manufacturing platform ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and YASKAWA Electric Corporation (TSE: 6506, President and CEO; Masahiro Ogawa, "YASKAWA") signed a definitive agreement ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help stre | ...

Investing.com – Japan stocks were lower after the close on Tuesday, as losses in the Precision Instruments, Gas & Water and ...

Investing.com – Japan stocks were higher after the close on Wednesday, as gains in the Machinery, Glass and Mining sectors led ...

Based on the memorandum of agreement signed in May, 2024, Astellas and YASKAWA have been advancing discussions toward establishing a joint venture to leverage their mutual strengths and accelerate ...

Astellas, YASKAWA agree to establish a JV focused on cell therapy manufacturing: Tokyo Friday, March 7, 2025, 10:00 Hrs [IST] Astellas Pharma Inc. and YASKAWA Electric Corporation ...

(RTTNews) - Japan's Astellas Pharma Inc. (ALPMY, ALPMY) announced that it has signed a definitive agreement with YASKAWA Electric Corp. to establish a joint venture for the development of a cell ...